FASEB J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Harvey, M.
Right arrow Articles by Donehower, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Harvey, M.
Right arrow Articles by Donehower, L. A.

The FASEB Journal, Vol 7, 938-943, Copyright © 1993 by The Federation of American Societies for Experimental Biology

RESEARCH COMMUNICATIONS

Genetic background alters the spectrum of tumors that develop in p53- deficient mice

M Harvey, MJ McArthur, CA Montgomery Jr, A Bradley and LA Donehower
Division of Molecular Virology, Baylor College of Medicine, Houston, Texas 77030.

Using gene targeting in embryonic stem cells, we have generated mice with one or two null p53 germ line alleles. Mice with both p53 alleles inactivated are developmentally normal but highly susceptible to the early development of spontaneous tumors. Initial studies were performed in mice with a mixed inbred genetic background (75% C57BL/6 and 25% 129/Sv) (Donehower et al., Nature (London) 356, 215-221, 1992). To study the effect of genetic background on tumorigenesis in p53- deficient mice, we have put the p53 null allele into a pure 129/Sv background and monitored tumor development. 129/Sv mice with two p53 null alleles developed tumors sooner than the mixed genetic background p53-deficient animals. The most frequently observed tumor in p53 null mice of both genetic backgrounds was a malignant lymphoma. Because the 129/Sv strain has a low incidence of lymphoma, the frequent occurrence of lymphomas in all p53 null mice suggests that this particular tumor type may be a direct result of p53 loss and not a result of a particular genetic background. In addition to malignant lymphomas, the 129/Sv p53-deficient mice showed an increased incidence of aggressive teratocarcinomas (8 of 18 tumor-bearing males), a tumor type rare in virtually all inbred mice except for 129 strains. Thus, it appears that loss of p53 may accelerate a prior tumor predisposition and that genetic background can play a role in mediating both the rate and spectrum of tumor development in these mice.


This article has been cited by other articles:


Home page
 Hum Mol GenetHome page
M.-Y. J. Lam, J. D. Heaney, K. K. Youngren, J. H. Kawasoe, and J. H. Nadeau
Trans-generational epistasis between Dnd1Ter and other modifier genes controls susceptibility to testicular germ cell tumors
Hum. Mol. Genet., September 15, 2007; 16(18): 2233 - 2240.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
A. C. Blackburn, L. Z. Hill, A. L. Roberts, J. Wang, D. Aud, J. Jung, T. Nikolcheva, J. Allard, G. Peltz, C. N. Otis, et al.
Genetic Mapping in Mice Identifies DMBT1 as a Candidate Modifier of Mammary Tumors and Breast Cancer Risk
Am. J. Pathol., June 1, 2007; 170(6): 2030 - 2041.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
A. Hilliard, B. Hilliard, S.-J. Zheng, H. Sun, T. Miwa, W. Song, R. Goke, and Y. H. Chen
Translational Regulation of Autoimmune Inflammation and Lymphoma Genesis by Programmed Cell Death 4
J. Immunol., December 1, 2006; 177(11): 8095 - 8102.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Biol.Home page
C. J. Lengner, H. A. Steinman, J. Gagnon, T. W. Smith, J. E. Henderson, B. E. Kream, G. S. Stein, J. B. Lian, and S. N. Jones
Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling.
J. Cell Biol., March 13, 2006; 172(6): 909 - 921.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. Dube, A. Bourdeau, K. M. Heinonen, A. Cheng, A. Lee Loy, and M. L. Tremblay
Genetic Ablation of Protein Tyrosine Phosphatase 1B Accelerates Lymphomagenesis of p53-Null Mice through the Regulation of B-Cell Development
Cancer Res., November 1, 2005; 65(21): 10088 - 10095.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
L. D. Mayo, Y. R. Seo, M. W. Jackson, M. L. Smith, J. R. Guzman, C. K. Korgaonkar, and D. B. Donner
Phosphorylation of Human p53 at Serine 46 Determines Promoter Selection and whether Apoptosis Is Attenuated or Amplified
J. Biol. Chem., July 15, 2005; 280(28): 25953 - 25959.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
S.-J. Zheng, S.-E. Lamhamedi-Cherradi, P. Wang, L. Xu, and Y. H. Chen
Tumor Suppressor p53 Inhibits Autoimmune Inflammation and Macrophage Function
Diabetes, May 1, 2005; 54(5): 1423 - 1428.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. P. Hussain, G. E. Trivers, L. J. Hofseth, P. He, I. Shaikh, L. E. Mechanic, S. Doja, W. Jiang, J. Subleski, L. Shorts, et al.
Nitric Oxide, a Mediator of Inflammation, Suppresses Tumorigenesis
Cancer Res., October 1, 2004; 64(19): 6849 - 6853.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. M. Reilly, R. G. Tuskan, E. Christy, D. A. Loisel, J. Ledger, R. T. Bronson, C. D. Smith, S. Tsang, D. J. Munroe, and T. Jacks
Susceptibility to astrocytoma in mice mutant for Nf1 and Trp53 is linked to chromosome 11 and subject to epigenetic effects
PNAS, August 31, 2004; 101(35): 13008 - 13013.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Pazzaglia, M. Mancuso, M. Tanori, M. J. Atkinson, P. Merola, S. Rebessi, V. Di Majo, V. Covelli, H. Hahn, and A. Saran
Modulation of Patched-Associated Susceptibility to Radiation Induced Tumorigenesis by Genetic Background
Cancer Res., June 1, 2004; 64(11): 3798 - 3806.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. Rooney, J. Sekiguchi, S. Whitlow, M. Eckersdorff, J. P. Manis, C. Lee, D. O. Ferguson, and F. W. Alt
Artemis and p53 cooperate to suppress oncogenic N-myc amplification in progenitor B cells
PNAS, February 24, 2004; 101(8): 2410 - 2415.
[Abstract] [Full Text] [PDF]

Home page
 GeneticsHome page
M.-Y. J. Lam, K. K. Youngren, and J. H. Nadeau
Enhancers and Suppressors of Testicular Cancer Susceptibility in Single- and Double-Mutant Mice
Genetics, February 1, 2004; 166(2): 925 - 933.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
J. M. Ward and D. E. Devor-Henneman
Mouse Models of Human Familial Cancer Syndromes
Toxicol Pathol, January 1, 2004; 32(1_suppl): 90 - 98.
[Abstract] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
H. Yoon, S. Liyanarachchi, F. A. Wright, R. Davuluri, J. C. Lockman, A. de la Chapelle, and N. S. Pellegata
Gene expression profiling of isogenic cells with different TP53 gene dosage reveals numerous genes that are affected by TP53 dosage and identifies CSPG2 as a direct target of p53
PNAS, November 26, 2002; 99(24): 15632 - 15637.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
C. A. Vaslet, N. J. Messier, and A. B. Kane
Accelerated Progression of Asbestos-Induced Mesotheliomas in Heterozygous p53+/- Mice
Toxicol. Sci., August 1, 2002; 68(2): 331 - 338.
[Abstract] [Full Text] [PDF]

Home page
 J. Exp. Med.Home page
Z. Qin, H.-J. Kim, J. Hemme, and T. Blankenstein
Inhibition of Methylcholanthrene-induced Carcinogenesis by an Interferon {gamma} Receptor-dependent Foreign Body Reaction
J. Exp. Med., June 3, 2002; 195(11): 1479 - 1490.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
M. Kalamarides, M. Niwa-Kawakita, H. Leblois, V. Abramowski, M. Perricaudet, A. Janin, G. Thomas, D. H. Gutmann, and M. Giovannini
Nf2 gene inactivation in arachnoidal cells is rate-limiting for meningioma development in the mouse
Genes & Dev., May 1, 2002; 16(9): 1060 - 1065.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
J. Lawler, W.-M. Miao, M. Duquette, N. Bouck, R. T. Bronson, and R. O. Hynes
Thrombospondin-1 Gene Expression Affects Survival and Tumor Spectrum of p53-Deficient Mice
Am. J. Pathol., November 1, 2001; 159(5): 1949 - 1956.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. Tsuzuki, A. Egashira, H. Igarashi, T. Iwakuma, Y. Nakatsuru, Y. Tominaga, H. Kawate, K. Nakao, K. Nakamura, F. Ide, et al.
Spontaneous tumorigenesis in mice defective in the MTH1 gene encoding 8-oxo-dGTPase
PNAS, September 25, 2001; 98(20): 11456 - 11461.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. G. Backlund, S. L. Trasti, D. C. Backlund, V. L. Cressman, V. Godfrey, and B. H. Koller
Impact of Ionizing Radiation and Genetic Background on Mammary Tumorigenesis in p53-deficient Mice
Cancer Res., September 1, 2001; 61(17): 6577 - 6582.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
R. E. Stoll, S. M. Furst, J. H. Stoltz, P. D. Lilly, and J. H. Mennear
Dermal Carcinogenicity in Transgenic Mice: Effect of Vehicle on Responsiveness of Hemizygous Tg.AC Mice to Phorbol 12-Myristate 13-Acetate (TPA)
Toxicol Pathol, August 1, 2001; 29(5): 535 - 540.
[Abstract] [PDF]

Home page
 Genes Dev.Home page
T. Ludwig, P. Fisher, S. Ganesan, and A. Efstratiadis
Tumorigenesis in mice carrying a truncating Brca1 mutation
Genes & Dev., May 15, 2001; 15(10): 1188 - 1193.
[Abstract] [Full Text]

Home page
 Toxicol SciHome page
J. E. Hulla, J. E. French, and J. K. Dunnick
Chromosome 11 Loss from Thymic Lymphomas Induced in Heterozygous Trp53 Mice by Phenolphthalein
Toxicol. Sci., April 1, 2001; 60(2): 264 - 270.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
J. E. Hulla, J. E. French, and J. K. Dunnick
Chromosome 11 allelotypes reflect a mechanism of chemical carcinogenesis in heterozygous p53-deficient mice
Carcinogenesis, January 1, 2001; 22(1): 89 - 98.
[Abstract] [Full Text] [PDF]

Home page
 CarcinogenesisHome page
J. E. French, G. D. Lacks, C. Trempus, J. K. Dunnick, J. Foley, J. Mahler, R. R. Tice, and R. W. Tennant
Loss of heterozygosity frequency at the Trp53 locus in p53-deficient (+/-) mouse tumors is carcinogen-and tissue-dependent
Carcinogenesis, January 1, 2001; 22(1): 99 - 106.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
J. French, R. D. Storer, and L. A. Donehower
The Nature of the Heterozygous Trp53 Knockout Model for Identifi cation of Mutagenic Carcinogens
Toxicol Pathol, January 1, 2001; 29(1_suppl): 24 - 29.
[Abstract] [PDF]

Home page
 Am. J. Pathol.Home page
C. Kuperwasser, G. D. Hurlbut, F. S. Kittrell, E. S. Dickinson, R. Laucirica, D. Medina, S. P. Naber, and D. J. Jerry
Development of Spontaneous Mammary Tumors in BALB/c p53 Heterozygous Mice : A Model for Li-Fraumeni Syndrome
Am. J. Pathol., December 1, 2000; 157(6): 2151 - 2159.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
K. M. D. La Perle, S. M. Jhiang, and C. C. Capen
Loss of p53 Promotes Anaplasia and Local Invasion in ret/PTC1-Induced Thyroid Carcinomas
Am. J. Pathol., August 1, 2000; 157(2): 671 - 677.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. J. Muller, A. K. Teresky, and A. J. Levine
A male germ cell tumor-susceptibility-determining locus, pgct1, identified on murine chromosome 13
PNAS, July 5, 2000; (2000) 140208197.
[Abstract] [Full Text]

Home page
 Arterioscler. Thromb. Vasc. Bio.Home page
C. D. Sigmund
Viewpoint: Are Studies in Genetically Altered Mice Out of Control?
Arterioscler. Thromb. Vasc. Biol., June 1, 2000; 20(6): 1425 - 1429.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
H. Honda, T. Ushijima, K. Wakazono, H. Oda, Y. Tanaka, S.-i. Aizawa, T. Ishikawa, Y. Yazaki, and H. Hirai
Acquired loss of p53 induces blastic transformation in p210bcr/abl-expressing hematopoietic cells: a transgenic study for blast crisis of human CML
Blood, February 15, 2000; 95(4): 1144 - 1150.
[Abstract] [Full Text] [PDF]

Home page
 J. Cell Sci.Home page
F Langa, C Kress, E Colucci-Guyon, H Khun, S Vandormael-Pournin, M Huerre, and C Babinet
Teratocarcinomas induced by embryonic stem (ES) cells lacking vimentin: an approach to study the role of vimentin in tumorigenesis
J. Cell Sci., January 10, 2000; 113(19): 3463 - 3472.
[Abstract] [PDF]

Home page
 Mol. Pharmacol.Home page
E. G. Schuetz, D. R. Umbenhauer, K. Yasuda, C. Brimer, L. Nguyen, M. V. Relling, J. D. Schuetz, and A. H. Schinkel
Altered Expression of Hepatic Cytochromes P-450 in Mice Deficient in One or More mdr1 Genes
Mol. Pharmacol., January 1, 2000; 57(1): 188 - 197.
[Abstract] [Full Text]

Home page
 Cancer Res.Home page
J. P. Lydon, G. Ge, F. S. Kittrell, D. Medina, and B. W. O'Malley
Murine Mammary Gland Carcinogenesis Is Critically Dependent on Progesterone Receptor Function
Cancer Res., September 1, 1999; 59(17): 4276 - 4284.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
R. V. Iozzo, F. Chakrani, D. Perrotti, D. J. McQuillan, T. Skorski, B. Calabretta, and I. Eichstetter
Cooperative action of germ-line mutations in decorin and p53 accelerates lymphoma tumorigenesis
PNAS, March 16, 1999; 96(6): 3092 - 3097.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
D. L. Cheo, D. K. Burns, L. B. Meira, J. F. Houle, and E. C. Friedberg
Mutational Inactivation of the Xeroderma Pigmentosum Group C Gene Confers Predisposition to 2-Acetylaminofluorene-induced Liver and Lung Cancer and to Spontaneous Testicular Cancer in Trp53-/- Mice
Cancer Res., February 1, 1999; 59(4): 771 - 775.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol PatholHome page
D. G. Rudmann and S. K. Durham
Utilization of Genetically Altered Animals in the Pharmaceutical Industry
Toxicol Pathol, January 1, 1999; 27(1): 111 - 114.
[Abstract] [PDF]

Home page
 J. Immunol.Home page
I. R. Rifkin, P. L. Channavajhala, H. L.B. Kiefer, A. J. Carmack, E. Landesman-Bollag, B. C. Beaudette, B. Jersky, D. J. Salant, S.-T. Ju, A. Marshak-Rothstein, et al.
Acceleration of lpr Lymphoproliferative and Autoimmune Disease by Transgenic Protein Kinase CK2{alpha}
J. Immunol., November 15, 1998; 161(10): 5164 - 5170.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
E. F. de Zoeten, V. Carr-Brendel, and E. P. Cohen
Resistance to Melanoma in Mice Immunized with Semiallogeneic Fibroblasts Transfected with DNA from Mouse Melanoma Cells
J. Immunol., March 15, 1998; 160(6): 2915 - 2922.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
S. N. Jones, A. T. Sands, A. R. Hancock, H. Vogel, L. A. Donehower, S. P. Linke, G. M. Wahl, and A. Bradley
The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of Mdm2
PNAS, November 26, 1996; 93(24): 14106 - 14111.
[Abstract] [Full Text] [PDF]

Home page
 Genes Dev.Home page
L J Ko and C Prives
p53: puzzle and paradigm.
Genes & Dev., May 1, 1996; 10(9): 1054 - 1072.
[PDF]

Home page
 Genes Dev.Home page
L A Donehower, L A Godley, C M Aldaz, R Pyle, Y P Shi, D Pinkel, J Gray, A Bradley, D Medina, and H E Varmus
Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability.
Genes & Dev., April 1, 1995; 9(7): 882 - 895.
[Abstract] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. J. Muller, A. K. Teresky, and A. J. Levine
A male germ cell tumor-susceptibility-determining locus, pgct1, identified on murine chromosome 13
PNAS, July 18, 2000; 97(15): 8421 - 8426.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by The Federation of American Societies for Experimental Biology.